Search Results

All Content Formulary Only Other Content

Scottish Formulary has compiled the following search results: We have found 18 results when searching "Bimekizumab"

DOCUMENT

30/03/2022 East Region formulary Committee Minutes

East Region Formulary ERFC Minutes 02 February 2022 Page 1 of 12 East Region Formulary Committee Minutes Date: 30 March 2022 Time: 2pm – 4:48pm Location: MS Teams Present: Ruth Cameron Advanc...

DOCUMENT

23/07/2025 East Region Formulary Committee Minutes

East Region Formulary ERFC Minutes 23 July 2025 Page 1 of 13 East Region Formulary Committee Minutes Date: 23 July 2025 Time: 2.00pm – 4:20pm Location: MS Teams Present: Ruth Cameron Advanced ...

DOCUMENT

13/05/2026 East Region Formulary Committee Minutes

East Region Formulary ERFC Minutes 13 May 2026 Page 1 of 15 East Region Formulary Committee Minutes Date: 13 May 2026 Time: 2.00pm – 4:20pm Location: MS Teams Present: Mona Boriceanu Advanced N...

DOCUMENT

28/05/2025 East Region Formulary Committee Minutes

East Region Formulary ERFC Minutes 28 May 2025 Page 1 of 15 East Region Formulary Committee Minutes Date: 28 May 2025 Time: 2.00pm – 4:15pm Location: MS Teams Present: Carla Capaldi Senior Pra...

FORMULARY DECISION

Bimekizumab : Bimzelx

SMC2605 : Alone or in combination with methotrexate, for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-m...

FORMULARY DECISION

Bimekizumab : Bimzelx

SMC2616 : Axial spondyloarthritis - For the treatment of adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C-reactive protein (...

FORMULARY DECISION

Bimekizumab : Bimzelx

SMC2698 : For the treatment of active moderate to severe hidradenitis suppurativa (HS) (acne inversa) in adults with an inadequate response to conventional systemic HS therapy. SMC restriction: for u...

FORMULARY DECISION

Bimekizumab : Bimzelx

SMC2410 : Treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. SMC restriction: for patients who have failed to respond to standard systemic therapies (i...